December 2024 Quarterly Activities Report and Appendix 4C

Emyria (ASX: EMD) is advancing in developing and delivering innovative treatments for mental health and neurological conditions, with significant achievements in the past quarter. Key highlights include ongoing progress in the PTSD treatment program, receiving ethics endorsement for psilocybin-assisted therapy, and expanding payer engagement for psychedelic-assisted therapy programs. The Empax Centre was selected for a sponsored psilocybin trial focused on adjustment disorder in cancer patients. Financial accomplishments include a successful $2.525M placement and receiving a net cash refund under the R&D Tax Incentive program. Additionally, Emyria finalized a global commercial license agreement for novel MDMA-inspired compounds with the University of Western Australia.

Following the quarter, Mr. Greg Hutchinson transitioned into the role of Executive Chairman, leveraging his expertise for the Company's growth. Dr. Michael Winlo assumed the position of Chief Scientific Officer, overseeing research, clinical trials, and drug development. Emyria remains focused on scaling its mental health treatment programs and establishing sustainable funding models for broader patient access. The Company's commitment to real-world data analysis and drug discovery efforts, such as the MDMA-inspired pipeline, continues to reinforce its position as a leader in advanced mental health care. Investors are encouraged to engage with us for more information or investment opportunities.